EC clears Roche’s Tecentriq SC as subcutaneous injection for multiple cancers
The approval was based on results from the Phase IB/III IMscin001 study which showed the SC formulation showed…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
17 Jan 24
The approval was based on results from the Phase IB/III IMscin001 study which showed the SC formulation showed…
17 Jan 24
The WuXiBody platform enables almost any mAb sequence pairs to be assembled into bispecific constructs that are expected…
16 Jan 24
Armatus Bio’s lead candidate for CMT1A has received orphan drug designation and rare paediatric drug designation from the…
16 Jan 24
PanDNA is designed to expand the array of sample types suitable for long-read sequencing, including cells, bacteria, blood,…
16 Jan 24
The IMPROVE-2 study enrolled 904 women and assigned randomly to the new drug therapy group against a monthly…
12 Jan 24
CSI is a clinical CRO that provides cost-effective clinical solutions through its team of experienced clinical research professionals…
12 Jan 24
Under the partnership, ElevateBio BaseCamp scientists will gain access to Xcellbio’s Avatar incubator system for cell therapy research…
12 Jan 24
Developed using Elicio’s lymph node targeting Amphiphile technology, ELI-002 is a structurally investigational therapeutic immunotherapy designed to target…
12 Jan 24
The partnership is intended to develop a suite of AI models to generate synthetically accessible biologically active compounds…
12 Jan 24
Illumina Ventures Labs is well positioned to enable early-stage companies to accelerate the time needed to reach their…